论文信息 - Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. - 字舞流文

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

T. Powles | S. Hughes | M. S. van der Heijden | S. Rudman | S. Chowdhury | M. Linch | Y. Tang | B. Szabados | A. Gómez de Liaño | N. van Dijk | A. Wimalasingham

[1] T. Powles,et al. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. , 2017, Cancer treatment reviews.

[2] R. Bourgon,et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[3] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[4] G. Sonpavde,et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. , 2011, The Lancet. Oncology.

[5] G. Sonpavde,et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. , 2010, The Lancet. Oncology.

[6] S. Ricci,et al. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[7] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.